Skip to content

Use of NERv's Inline Device as an Early Diagnostic Method for Anastomotic Leak.

Use of NERv's Inline Device for the Continuous Monitoring of pH and Conductance Measurements as an Early Diagnostic Method for Anastomotic Leak.

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04253028
Enrollment
9
Registered
2020-02-05
Start date
2020-01-29
Completion date
2020-03-15
Last updated
2020-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anastomotic Leak

Brief summary

NERv's early feasibility clinical trial is a first-in-human, multi-center, pre-market, non-randomized clinical trial intended to evaluate the safety and collect preliminary data necessary for the detection of clinical post-operative anastomotic/intraperitoneal leakages. NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains. The purpose of NERv's feasibility clinical trial is to collect pH and conductance readings by analyzing peritoneal drainage fluid. Upon analyzing data collected from NERv's Inline Device a clinical model of pH and conductance will be created. The clinical model can then be used to determine if a complication is developing. For instance, boundaries (reading thresholds) can be established where if the signal goes outside the boundaries a complication could be identified. Specifically the ability to detect a post-operative complication known as anastomotic leakage; which is a dreaded complication associated with abdominal surgeries; will be the main focus of the study.

Interventions

NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.

Sponsors

Unity Health Toronto
CollaboratorOTHER
FluidAI Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 years - male or female * Subject understands and has voluntarily signed and dated Informed Consent Form (ICF) * Subjects must be willing to comply with trial requirements * Subject has a peritoneal drain attached post-surgery

Exclusion criteria

* Plans that the subject will be discharged less than 8 hours post-surgery * Involvement in the planning and conduct of the clinical investigation * Subject is participating in another investigational drug or device study which would interfere with the endpoints and follow-ups of this study * Subject is consuming steroid or anti-inflammatory medication

Design outcomes

Primary

MeasureTime frameDescription
Change in pH of Peritoneal FluidA clinical model of change in pH over time will be established once the study is completed (up to 28 weeks).NERv's Inline Device will be collecting continuous pH measurements of fluid that travels across the peritoneal drain of bariatric surgery patients.
Change in Conductance of Peritoneal FluidA clinical model of change in conductance over time will be established once the study is completed (up to 28 weeks).NERv's Inline Device will be collecting continuous conductance measurements of fluid that travels across the peritoneal drain of bariatric surgery patients.
Change in Temperature of Peritoneal FluidA clinical model of change in temperature over time will be established once the study is completed (up to 28 weeks).NERv's Inline Device will be collecting continuous temperature measurements of fluid that travels across the peritoneal drain of bariatric surgery patients.
Number of Subjects with Device Related Adverse EventsThe number of device related will be established once the study is completed (up to 28 weeks).an adverse event assesmtent will be performed in accordance to ISO 14155 standards to determine the number of device related adverse events.

Secondary

MeasureTime frameDescription
Investigator and Subject Feedback on Device's Ease of Use and Comfort levelOverall comfort level and ease of use will be established once the study is completed (up to 28 weeks).Ease of use and comfort levels will be evaluated by collecting responses to a questionnaire that will be filled out by both the investigator/nurse and the subject.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026